廣告

Johnson & Johnson to buy Actelion for $30bln

U.S. healthcare giant Johnson & Johnson will buy Swiss biotech company Actelion in a $30 billion all-cash deal that includes spinning off Actelion's research and development pipeline. Ivor Bennett reports